Dosimetrically triggered adaptive radiotherapy for head and neck cancer: Considerations for the implementation of clinical protocols.

adaptive radiotherapy dosimetrically triggered adaptation external beam radiotherapy-photons head and neck cancer protocol implementation

Journal

Journal of applied clinical medical physics
ISSN: 1526-9914
Titre abrégé: J Appl Clin Med Phys
Pays: United States
ID NLM: 101089176

Informations de publication

Date de publication:
Nov 2023
Historique:
revised: 25 05 2023
received: 09 03 2023
accepted: 18 06 2023
pubmed: 14 7 2023
medline: 14 7 2023
entrez: 14 7 2023
Statut: ppublish

Résumé

Defining dosimetric rules to automatically detect patients requiring adaptive radiotherapy (ART) is not straightforward, and most centres perform ad-hoc ART with no specific protocol. This study aims to propose and analyse different steps to design a protocol for dosimetrically triggered ART of head and neck (H&N) cancer. As a proof-of-concept, the designed protocol was applied to patients treated in TomoTherapy units, using their available software for daily MVCT image and dose accumulation. An initial protocol was designed by a multidisciplinary team, with a set of flagging criteria based only on dose-volume metrics, including two action levels: (1) surveillance (orange flag), and (2) immediate verification (red flag). This protocol was adapted to the clinical needs following an iterative process. First, the protocol was applied to 38 H&N patients with daily imaging. Automatic software generated the daily contours, recomputed the daily dose and flagged the dosimetric differences with respect to the planning dose. Second, these results were compared, by a sensitivity/specificity test, to the answers of a physician. Third, the physician, supported by the multidisciplinary team, performed a self-analysis of the provided answers and translated them into mathematical rules in order to upgrade the protocol. The upgraded protocol was applied to different definitions of the target volume (i.e. deformed CTV + 0, 2 and 4 mm), in order to quantify how the number of flags decreases when reducing the CTV-to-PTV margin. The sensitivity of the initial protocol was very low, specifically for the orange flags. The best values were 0.84 for red and 0.15 for orange flags. After the review and upgrade process, the sensitivity of the upgraded protocol increased to 0.96 for red and 0.84 for orange flags. The number of patients flagged per week with the final (upgraded) protocol decreased in median by 26% and 18% for red and orange flags, respectively, when reducing the CTV-to-PTV margin from 4 to 2 mm. This resulted in only one patient flagged at the last fraction for both red and orange flags. Our results demonstrate the value of iterative protocol design with retrospective data, and shows the feasibility of automatically-triggered ART using simple dosimetric rules to mimic the physician's decisions. Using a proper target volume definition is important and influences the flagging rate, particularly when decreasing the CTV-to-PTV margin.

Identifiants

pubmed: 37448193
doi: 10.1002/acm2.14095
pmc: PMC10647964
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14095

Informations de copyright

© 2023 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, LLC on behalf of The American Association of Physicists in Medicine.

Références

Radiat Oncol. 2018 Apr 27;13(1):80
pubmed: 29699582
Phys Med Biol. 2010 Jun 7;55(11):N329-36
pubmed: 20442461
Med Phys. 2014 Dec;41(12):121712
pubmed: 25471959
Radiother Oncol. 2015 Jul;116(1):57-63
pubmed: 26142268
J Appl Clin Med Phys. 2010 Jul 02;11(4):3229
pubmed: 21081878
J Appl Clin Med Phys. 2023 Nov;24(11):e14095
pubmed: 37448193
Nat Methods. 2021 Feb;18(2):203-211
pubmed: 33288961
Phys Med Biol. 2005 Feb 21;50(4):655-80
pubmed: 15773626
Semin Radiat Oncol. 2019 Jul;29(3):185-197
pubmed: 31027636
Biomed Mater Eng. 2015;26 Suppl 1:S1037-44
pubmed: 26405859
Radiother Oncol. 2020 Jan;142:115-123
pubmed: 31653573
Radiother Oncol. 2019 Sep;138:68-74
pubmed: 31146073
Jpn J Radiol. 2013 Sep;31(9):593-9
pubmed: 23749480
Head Neck. 2014 Nov;36(11):1541-6
pubmed: 23996502
Cancer Radiother. 2022 Feb-Apr;26(1-2):59-75
pubmed: 34953713
Phys Med Biol. 1997 Jan;42(1):123-32
pubmed: 9015813
Phys Med Biol. 2005 Sep 21;50(18):4259-76
pubmed: 16148392
Radiother Oncol. 2020 Dec;153:88-96
pubmed: 32579998
J Med Internet Res. 2021 Jul 12;23(7):e26151
pubmed: 34255661
Radiother Oncol. 2019 Jun;135:130-140
pubmed: 31015159
Strahlenther Onkol. 2012 Mar;188(3):243-7
pubmed: 22294198
Radiat Oncol. 2015 Jan 09;10:6
pubmed: 25573091
Semin Radiat Oncol. 2005 Jul;15(3):168-79
pubmed: 15983942
Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):567-580
pubmed: 31276776
Lancet Oncol. 2012 Jul;13(7):e292-300
pubmed: 22748268
Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):e47-54
pubmed: 23122981
Radiother Oncol. 2015 Jun;115(3):285-94
pubmed: 26094076
Med Phys. 2018 Oct;45(10):4558-4567
pubmed: 30136285
J Appl Clin Med Phys. 2016 Mar 08;17(2):328-340
pubmed: 27074457
J Appl Clin Med Phys. 2012 Sep 06;13(6):3986
pubmed: 23149791
Radiother Oncol. 2017 Dec;125(3):392-397
pubmed: 29162279
Med Phys. 2009 Sep;36(9):4268-76
pubmed: 19810501
Cancer Radiother. 2016 Sep;20 Suppl:S36-60
pubmed: 27516050
Radiother Oncol. 2020 Feb;143:117-125
pubmed: 32063377

Auteurs

Ana M Barragán-Montero (AM)

UCLouvain, Center of Molecular Imaging, Radiotherapy and Oncology (MIRO), Brussels, Belgium.

Geneviève Van Ooteghem (G)

UCLouvain, Center of Molecular Imaging, Radiotherapy and Oncology (MIRO), Brussels, Belgium.
Department of Radiation Oncology, Cliniques universitaires Saint-Luc, Brussels, Belgium.

Damien Dumont (D)

UCLouvain, Center of Molecular Imaging, Radiotherapy and Oncology (MIRO), Brussels, Belgium.
Department of Radiation Oncology, Cliniques universitaires Saint-Luc, Brussels, Belgium.

Sara Teruel Rivas (ST)

UCLouvain, Center of Molecular Imaging, Radiotherapy and Oncology (MIRO), Brussels, Belgium.

Edmond Sterpin (E)

UCLouvain, Center of Molecular Imaging, Radiotherapy and Oncology (MIRO), Brussels, Belgium.
Department of Oncology, Laboratory of Experimental Radiotherapy, KU Leuven, Leuven, Belgium.

Xavier Geets (X)

UCLouvain, Center of Molecular Imaging, Radiotherapy and Oncology (MIRO), Brussels, Belgium.
Department of Radiation Oncology, Cliniques universitaires Saint-Luc, Brussels, Belgium.

Classifications MeSH